Predictive value of KRAS mutations in chemoresistant CRC

被引：30

作者：

Lievre, Astrid ^{[2
]}

Laurent-Puig, Pierre ^{[1
]}

机构：

[1] Univ Paris 05, Sch Med, F-75006 Paris, France

[2] INSERM Lab, Paris, France

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 06期

关键词：

METASTATIC COLORECTAL-CANCER; K-RAS MUTATIONS; CETUXIMAB; PANITUMUMAB;

D O I：

10.1038/nrclinonc.2009.69

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

on the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

引用

页码：306 / 307

页数：3

共 50 条

[41] KRAS - Are All KRAS Mutations the Same?
Stinchcombe, Thomas E.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S129 - S129
[42] Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
Ucar, Gokhan
Ergun, Yakup
Esen, Selin Akturk
Acikgoz, Yusuf
Dirikoc, Merve
Esen, Irfan
Bal, Oznur
Uncu, Dogan
MEDICINE, 2020, 99 (39) : E22407
[43] Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases
Tonello, M.
Baratti, D.
Sammartino, P.
Di Giorgio, A.
Robella, M.
Sassaroli, C.
Framarini, M.
Valle, M.
Macri, A.
Graziosi, L.
Coccolini, F.
Lippolis, P., V
Gelmini, R.
Deraco, M.
Biacchi, D.
Aulicino, M.
Vaira, M.
De Franciscis, S.
Acapito, F.
Carboni, F.
Milone, E.
Donini, A.
Fugazzola, P.
Faviana, P.
Sorrentino, L.
Pizzolato, E.
Cenzi, C.
Del Bianco, P.
Sommariva, A.
ESMO OPEN, 2024, 9 (04)
[44] THE VALUE OF KRAS MUTATIONAL STATUS AS A PREDICTIVE BIOMARKER IN METASTATIC COLORECTAL CANCER
Tsoukalas, N. G.
Bagos, P.
Papakostidi, A.
Hamodrakas, S.
Lypas, G. D.
Barbounis, V.
ANNALS OF ONCOLOGY, 2010, 21 : 76 - 76
[45] Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer
Shigenori Kadowaki
Miho Kakuta
Shuhei Takahashi
Akemi Takahashi
Yoshiko Arai
Yoji Nishimura
Toshimasa Yatsuoka
Akira Ooki
Kensei Yamaguchi
Keitaro Matsuo
Kei Muro
Kiwamu Akagi
World Journal of Gastroenterology, 2015, 21 (04) : 1275 - 1283
[46] Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancer
Jugovic, Dragana
Nikolic, Marija Vukelic
Madic, Visnja
Brankovic, Ljiljana
Milicevic, Radovan
Stanojevic, Goran
Vasiljevic, Perica
REVISTA ROMANA DE MEDICINA DE LABORATOR, 2021, 29 (04): : 365 - 375
[47] Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).
Tomasini, Pascale
Jao, Kevin
Kamel-Reid, Suzanne
Stockley, Tracy
Tsao, Ming Sound
Liu, Geoffrey
Leighl, Natasha B.
Feld, Ronald
Bradbury, Penelope Ann
Pintilie, Melania
Mascaux, Celine
Shepherd, Frances A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[48] Predictive value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with chemotherapy (CT)
Dingemans, Anne-Marie C.
Smit, Egbert F.
Derks, Jules
Mellema, Wouter
Heideman, Danielle
Van Suylen, Robertjan
Thunnissen, Erik
CANCER RESEARCH, 2011, 71
[49] Analysis of KRAS mutations in colorectal cancer (CRC) patients by gender in a Brazilian cohort of 3,346 patients
Ferreira, C. G.
Zalcberg-Renault, I.
Vieira, F. M.
Bonamino, M. H.
Zalis, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[50] Prognostic and Predictive Implications of EGFR Mutations, EGFR Copy Number and KRAS Mutations in Advanced Stage Lung Adenocarcinoma
Bonanno, Laura
Schiavon, Marco
Nardo, Giorgia
Bertorelle, Roberta
Bonaldi, Laura
Galligioni, Alessandra
Indraccolo, Stefano
Pasello, Giulia
Rea, Federico
Favaretto, Adolfo
ANTICANCER RESEARCH, 2010, 30 (12) : 5121 - 5128

← 1 2 3 4 5 →